Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes.

三优生物与愚公生物今日宣布签署战略合作协议。这一强强联合标志着双方在高端合成分子酶的开发合作上迈出了重要的一步。

This collaboration is based on a strong mutual consensus: Sanyou Bio possesses profound expertise in innovative biopharmaceutical discovery and development, while Yugong Bio holds core advantages in enzyme engineering and large-scale production. This powerful alliance will focus on the entire chain of enzyme product R&D, production, and application.

此次合作基于双方强大的共识：三优生物在创新生物药物发现与开发方面具备深厚的专业知识，而愚公生物在酶工程和大规模生产方面拥有核心优势。这一强大联盟将专注于酶产品从研发、生产到应用的整个链条。

By seamlessly integrating their respective superior resources, the partners aim to jointly overcome key technological bottlenecks in the biopharmaceutical field, committed to driving cost reduction, efficiency improvement, and technological innovation across the industry. This forward-looking strategic layout not only marks a new phase for the collaboration but also injects fresh momentum into the high-quality development of China's biopharmaceutical industry..

通过无缝整合各自的优势资源，合作伙伴旨在共同克服生物制药领域的关键技术瓶颈，致力于推动全行业的降本增效与技术创新。这一前瞻性的战略布局不仅标志着双方合作迈入新阶段，也为我国生物制药产业的高质量发展注入了新动能。

Powerful Synergy: Complementary Strengths Form a Solid Foundation for Cooperation

强大的协同效应：互补优势为合作奠定坚实基础

Sanyou Bio is a biotechnology company focused on the discovery and development of innovative antibody drugs. Its internationally leading ultra-trillion-scale antibody library, combined with the dual drivers of 'Efficient Screening + AI Analysis,' forms a powerful drug discovery engine. This platform enables rapid screening from massive libraries to precise candidates, significantly accelerating early-stage drug discovery and providing solid foundational innovation for R&D.

三优生物是一家专注于创新抗体药物发现与开发的生物技术公司，其国际领先的超万亿级抗体库，结合“高效筛选＋AI分析”双轮驱动，形成了强大的药物发现引擎。该平台能够从海量库中快速筛选出精准候选物，显著加速早期药物发现，为研发提供坚实的基础创新。

This unique advantage injects a powerful 'source of innovation' into early drug R&D, with its vast library capacity and exceptional screening efficiency already becoming an industry tool for accelerating drug discovery..

这一独特优势为早期药物研发注入了强大的“创新源泉”，其庞大的库容量和卓越的筛选效率已经成为加速药物发现的行业工具。

Yugong Bio is a national high-tech enterprise focusing on upstream molecular enzyme reagents for synthetic biology and their application solutions. The company possesses strong capabilities in enzyme molecular engineering and cell-free protein synthesis. Its enzyme products are renowned for high purity, high activity, and high stability, widely used in basic life science research, biopharmaceutical production, and bio-industrial fields, offering highly differentiated competitive advantages.

愚公生物是一家专注于合成生物学上游分子酶试剂及其应用解决方案的国家高新技术企业，公司具备强大的酶分子工程能力和无细胞蛋白合成能力，其酶产品以高纯度、高活性、高稳定性著称，广泛应用于基础生命科学研究、生物医药生产和生物工业领域，具有高度差异化的竞争优势。

Leveraging its deep expertise in enzyme engineering, Yugong Bio provides customers with stable, reliable, and cost-effective enzyme-related products and services..

利用其在酶工程方面的深厚专业知识，禹贡生物为客户提供稳定、可靠且具有成本效益的酶相关产品和服务。

Collaborative Win-Win: Strategic Cooperation Opens a New Future

合作共赢：战略合作开启新未来

This strategic collaboration is based on both parties' profound understanding of industry trends and high recognition of each other's technical capabilities. It aims to create core value through deep synergy across three levels:

此次战略合作基于双方对行业趋势的深刻理解和对彼此技术能力的高度认可，旨在通过三个层面的深度协同创造核心价值：

1.  Resource Complementarity: Building End-to-End Capability from 'Discovery'

1. 资源互补性：从“发现”开始构建端到端的能力

to 'Delivery': Sanyou Bio will utilize its trillion-scale molecular library and efficient screening platform to support Yugong Bio's enzyme optimization and engineering for specific application scenarios. Yugong Bio will leverage its mature enzyme product R&D and large-scale production system to ensure the quality and stable supply of co-developed products.

对于“交付”：三优生物将利用其万亿级分子库和高效的筛选平台，支持愚公生物在特定应用场景下的酶优化与工程化。愚公生物将依托其成熟的酶产品开发和大规模生产体系，确保共同开发产品的质量和稳定供应。

This integrated 'Discovery + Optimization + Production' model will greatly accelerate the R&D industrialization process..

这种“发现+优化+生产”一体化的模式将大大加快研发产业化进程。

2.  Market Win-Win: Creating Cutting-Edge Products with Better Cost-Effectiveness:

2. 市场双赢：以更优的成本效益创造尖端产品：

Through joint R&D and supply chain coordination, the partners aim to develop enzyme preparations and solutions with superior performance and lower cost. This will not only help reduce the R&D and production costs for both parties but also provide more cost-effective products for downstream customers, especially in fields like biopharmaceutical R&D and in vitro diagnostics, enhancing their market competitiveness..

通过共同研发和供应链协调，双方旨在开发出性能更优、成本更低的酶制剂和解决方案。这不仅有助于降低双方的研发和生产成本，还能为下游客户提供更具性价比的产品，尤其是在生物制药研发和体外诊断等领域，提升其市场竞争力。

3.  Industry Empowerment: Catalyzing Next-Generation Innovative Solutions

3. 产业赋能：催化下一代创新解决方案

: This collaboration represents a deep integration of cutting-edge molecular discovery capabilities and advanced enzyme engineering technology. It holds the potential to catalyze a batch of innovative enzyme products and solutions that lead the future, injecting new momentum into the entire biopharmaceutical industry..

此次合作代表了前沿分子发现能力与先进酶工程技 术的深度整合，有望催生一批引领未来的创新酶产品与解决方案，为整个生物医药产业注入新动能。

Dr. David Lang, Founder and CEO of Sanyou Bio, stated:

朗博士，三友生物创始人兼首席执行官，表示：

'The collaboration with Yugong Bio represents a deep coupling of cutting-edge molecular discovery capabilities and advanced enzyme engineering technology. We firmly believe that this strategic synergy will go beyond simple addition of advantages, transcend single, isolated R&D efforts, and create a seamlessly connected value loop, thereby accelerating scientific innovation and the commercial success of branded products.'.

“与毓贡生物的合作，是前沿分子发现能力与先进酶工程技术创新的深度融合。我们深信，这一战略协同将超越优势的简单叠加，突破单一、孤立的研发努力，创造无缝连接的价值闭环，从而加速科学创新和品牌产品的商业成功。”

Dr. Henghao Xu, Founder and CEO of Yugong Bio, stated:

徐恒浩博士，愚公生物创始人兼首席执行官，表示：

'The strategic collaboration with Sanyou Bio is a significant step in Yugong Bio's development journey. Sanyou's exceptional capabilities in ultra-large capacity molecular libraries and screening will inject strong momentum into the foundational innovation of our enzyme products. We are confident that through close cooperation, we can bring more breakthrough products to the market, achieving win-win development.'.

“与三优生物的战略合作是愚公生物发展历程中的重要一步。三优在超大容量分子库和筛选方面卓越的能力，将为我们的酶制剂产品的基础创新注入强劲动力。我们相信，通过紧密合作，能够将更多突破性产品推向市场，实现共赢发展。”

The strategic collaboration between Sanyou Bio and Yugong Bio is not merely a powerful alliance of complementary strengths but also a key milestone, marking a solid step forward in their journey to deepen industrial synergy and build core technological barriers.

三优生物与愚公生物的战略合作不仅仅是优势互补的强强联合，更是标志着双方在深化产业协同、构筑核心技术壁垒的征程中迈出了坚实的一步，是具有里程碑意义的关键事件。

About Yugong Bio

关于愚公生物

Jiangsu Yugong Biotechnology Co., Ltd. primarily addresses the 'bottleneck' situation of upstream molecular enzyme raw materials in domestic synthetic biology and biopharmaceuticals, committed to providing more high-quality, economical, user-friendly enzyme products with independent intellectual property rights.

江苏愚公生物技术有限公司主要解决国内合成生物学、生物医药上游分子酶原料的“卡脖子”情况，致力于提供更优质、更经济、更易用的、拥有自主知识产权的酶产品。

The company headquarters is located in the China (Jiangsu) Pilot Free Trade Zone Lianyungang Area, constructed and managed with reference to GMP standards; its wholly-owned subsidiary Jiangsu Baisimei Biotechnology Co., Ltd., located in the Lianyungang National High-Tech Zone, is mainly responsible for R&D and research reagent production.

公司总部位于中国（江苏）自由贸易试验区连云港片区，按照GMP标准建设与管理；其全资子公司江苏百斯迈生物科技有限公司，位于连云港国家级高新技术产业开发区，主要负责研发和科研试剂的生产。

The company adheres to independent R&D as its core and has established domestically leading cell-free protein synthesis and toxic protein recombinant expression technology platforms. It has been certified as a National High-Tech Enterprise and has obtained ISO13485 Quality Management System certification..

公司以自主研发为核心，建立了国内领先的无细胞蛋白合成、毒性蛋白重组表达技术平台，被评为国家高新技术企业，并获得ISO13485质量管理体系认证。

The company was the first in China to achieve large-scale production of the DNA 'molecular scissors' – restriction endonucleases, breaking the complete monopoly of foreign companies for over 40 years. It currently ranks among the top three in the domestic restriction enzyme market share and has entered the supply chains of several leading domestic synthetic biology upstream enterprises.

该公司是中国首家实现DNA“分子剪刀”——限制性内切酶大规模量产的企业，打破了国外公司长达40多年的完全垄断。目前在国内限制酶市场份额中排名前三，并进入了多家国内合成生物学上游领先企业的供应链。

The company now possesses over 100 products across 11 series including restriction enzymes, cell-free protein synthesis, modification & cloning, PCR, isothermal amplification, reverse transcription, quantitative real-time PCR, and in vitro transcription, widely used in gene synthesis, molecular diagnostics, biomedical research, and other fields..

该公司现已拥有包括限制酶、无细胞蛋白合成、修饰与克隆、PCR、等温扩增、逆转录、定量实时PCR、体外转录等11个系列的百余种产品，广泛应用于基因合成、分子诊断、生物医药研究等领域。

About Sanyou Bio

关于三友生物

Sanyou Bio is a high-tech biopharmaceutical enterprise driven by its mission to 'Enable Easy Innovation of Biologics for All' and powered by its ultra-trillion-scale molecular libraries and intelligent technology.

三优生物是一家以“让天下生物药创新变得容易”为使命，拥有超万亿规模分子库和智能化技术的高科技生物医药企业。

The company is dedicated to building a globally top-tier original innovation factory for new drugs. It centers on the AI-powered Super-Trillion Antibody Library (AI-STAL); relies on its integrated, intelligent, and internationally leading innovative biologics R&D platform combining in silico and wet-lab approaches; and promotes the R&D and industrialization of global innovative drugs through diversified business models..

公司致力于打造全球顶尖的原创新药创新工厂，以AI超万亿抗体库（AI-STAL）为核心，依托其整合的、智能化的、国际领先的干湿结合创新型生物药研发平台，通过多元化商业模式推动全球创新药物的研发和产业化。

The company is headquartered in Shanghai, China, and has established business centers in Asia, North America, Europe, and other regions, forming a global business network. It currently has over 20,000 square meters of R&D and GMP facilities in operation or under development.

该公司总部位于中国上海，并在亚洲、北美、欧洲及其他地区建立了业务中心，形成了全球业务网络。目前，公司拥有超过20,000平方米的研发和GMP设施在运营或正在开发中。

The company has established sound cooperative relationships with over 2,000 pharmaceutical companies and biotechnology firms globally, has empowered more than 1,200 new drug R&D projects, and has completed over 50 cooperative R&D projects, more than 10 of which have advanced to the IND and clinical development stages..

该公司已与全球超过2000家制药公司和生物技术公司建立了良好的合作关系，助力1200多个新药研发项目，完成50余个合作研发项目，其中10余个已推进至IND及临床开发阶段。

The company has filed for over 130 invention patents, more than 30 of which have been granted. It has also obtained over 10 qualifications and system certifications including National High-Tech Enterprise, Shanghai Specialized, Refined, Distinctive, and New (SRDN) Enterprise, ISO9001, and ISO27001.

该公司申请了130多项发明专利，其中30多项已获授权，并获得了包括国家高新技术企业、上海市专精特新企业、ISO9001、ISO27001等在内的10余项资质和体系认证。

Source: prnewswire.com

来源：prnewswire.com